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Major histocompatibility complex class II HLA-DR molecules are plasma-membrane integral heterodimers, constitutively
expressed in antigen-presenting cells. Their expression is known to be upregulated in peripheral T lymphocytes upon cell
activation and to be constitutive in T cell lines. In H78-C10.0, a subclone of the human CD4 T cell line HUT-78, the transport
of MHC class II HLA-DR molecules is blocked, resulting in their localization within internal vesicular compartments rather
than at the cell surface. In this article, we show that HIV-1HX10 infection of H78-C10.0 cells induces HLA-DR surface
expression. Moreover, the produced infectious viruses harbor the heterodimer molecules in their envelopes. To define which
of the viral proteins was involved in this phenomenon, we infected H78-C10.0 cells with recombinant vaccinia vectors
containing either the gag-pro coding sequence or the entire env gene. Only gag expression was able to induce HLA-DR
cell-surface localization in H78-C10.0 cells. RT-PCR analysis of the infected cells revealed no significant alteration in the
amount of HLA-DR-specific RNA compared to untreated cells. This implies that Gag acts on downstream events. When the
env viral gene, coding for the precursor glycoprotein gp160, was expressed in H78-C10.0, the Env protein targeted to the cell
surface was poorly processed to its final mature forms gp120 and gp41. However, coexpression of the env and gag genes
led to restoration of this phenotype. Although the mechanism is unknown, the data compiled in this study strongly suggest
that the viral Gag protein can interact with the cellular trafficking apparatus. Moreover, in a specific cell type as H78-C10.0fects.
; MHC;INTRODUCTION
Retroviruses acquire their surrounding envelope
through budding at the plasma membrane of the infected
cell. This phenomenon is known to be initiated and
coordinated by uncleaved viral Gag precursor at the
cytoplasmic face of the budding membrane, in the ab-
sence of any other viral polypeptide (reviewed in Garoff
et al., 1998). Experiments dealing with the characteriza-
tion of the protein content of the viral envelope show that
some but not all cell membrane associated proteins are
incorporated into the viral phospholipid bilayer (Zavada,
1982; reviewed in Ott, 1997), suggesting that a molecular
sorting directed by viral determinants might take place
during the budding event. One of the most representative
protein components of this envelope is the class II major
histocompatibility complex HLA-DR heterodimer (Arthur
et al., 1992; Gluschankof et al., 1997; Ott, 1997; Saarlos et
al., 1997). These molecules are constitutively expressed
at the cell surface of antigen-presenting cells as well as
activated T lymphocytes. They are composed of two
different trans-membrane chains ( and ) that, upon
interaction with the Invariant chain (Ii) in the lumen of the
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160endoplasmic reticulum, follow the secretory pathway to
the plasma membrane. Encounter with the antigenic
peptides occurs in a late endocytic multivesicular bodies
(MVB) compartment known as the class II compartment,
MIIC (Amigorena et al., 1994). Although no specific infor-
mation is available concerning the role of HLA-DR mol-
ecules in the replication cycle of HIV-1, a direct correla-
tion was reported between viral infectivity and the pres-
ence of HLA-DR at the surface of the virus (P.
Gluschankof and M. Suzan, unpublished observation;
Cantin et al., 1997). One invoked explanation is that a
tight contact, during the first steps of viral infection, might
be reinforced through specific molecular interactions be-
tween HLA-DR on the viral surface and CD4/CD3 on the
target cell surface. It is known that HIV-1 has developed
strategies to modify various host cell functions to opti-
mize its replication (Trono, 1995). In particular, it has
been shown that the expression of certain viral-encoded
proteins alone disturbs either transcriptional or post-
translational events in a similar manner as observed in
the infected cell (reviewed in Frankel, 1998). In terms of
intracellular protein transport modifications, the most
striking effects were observed when the viral nef gene
was expressed. Reported data clearly showed that CD4
as well as MHC class I  chain molecules of the A andthis interaction can even reverse intracellular transport de
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cell trafficking.
B but not C haplotypes are downregulated from the cell
surface upon HIV-1 infection through direct interactions
between Nef and soluble cellular proteins known to be
involved in the endocytic machinery (Aiken et al., 1994;
Benichou et al., 1994; LeGall et al., 1998). This efficient
phenomenon leads to mislocalization of class I mole-
cules to degrading cellular compartments (Mangasarian
and Trono, 1997; Trono, 1995). Another interesting feature
in infection-dependent cellular function modification is
the viral budding event. This membrane deformation pro-
cess, that is absent in noninfected cells, is governed
solely by the expression product of the viral gag gene,
namely Pr55gag, a precursor of the matrix, capsid, and
nucleocapsid structural viral proteins as well as of p6,
p2, and p1. Some indirect evidence, such as cell-line
dependency of pseudoviral particle formation upon Gag
expression (Dru et al., 1994; Parker and Hunter, 2000),
suggests the implication of nonessential cellular mole-
cules as partner(s) to virus budding. To reach the inner
face of the plasma membrane of the infected cell, retro-
viral Gag might have to interact with the intracellular
transport machinery as has been suggested elsewhere
(Yuan et al., 1993). In accordance with this, it can be
inferred that this viral-to-cell molecular interaction could
result in some changes in cellular protein transport. In
the present article we analyze the modifications of
HLA-DR intracellular localization induced by expression
of the HIV-1 gag gene in a CD4 human T cell line
lacking HLA-DR surface expression. The relevance of
our results to the involvement of an endosomal sorting
protein in Pr55gag budding, i.e., tsg101 (Garrus et al.,
2001; VerPlank et al., 2001), is discussed.
RESULTS
HLA-DR molecules are absent at the cell surface of
H78-C10.0 cells, but present at low levels in
intracellular compartments
In the course of a project studying the possible impli-
cation of HLA-DR heterodimers in HIV-1 infection, we
purified by limiting dilution two subclones of HUT78
cells, a CD4low HLA-DR T human cell line, that we
further characterized by FACS surface analysis (Table 1).
Among 18 different T cell surface antigens tested, the
most striking difference observed between those two
clones was the level of HLA-DR expression at their
plasma membrane. Both clones were CD4low. The first
clone, named H78-C10.0, was negative for HLA-DR sur-
face expression, whereas the second one, H78-D2.2,
was highly positive for HLA-DR (Fig. 1A). The fact that
HLA-DR  and  chains were immunoprecipitated from
H78-C10.0 cell extracts (Fig. 1B) suggests that the lack of
this heterodimer cell surface expression might be the
resultant of its, somehow specific, retention within an
intracellular compartment. Our results also show that
H78-C10.0 cells express less HLA-DR molecules than
the H78-D2.2 subclone (compare in Fig. 1B Lane 1, 5 
105H78-D2.2 cells, and Lane 3, 107 H78-C10.0 cells). To
determine the localization of the class II heterodimers in
H78-C10.0 cells, we performed immunofluorescence
staining on permeabilized cells using monoclonal anti-
bodies recognizing the / complex. As seen in Fig. 1C,
H78-D2.2 cells present, in addition to a strong HLA-DR
surface localization, an intracellular staining in an endo-
cytic LAMP-2-like compartment. Only a faint punctuated
signal above background, resembling post-Golgian
staining but not LAMP-2-like endocytic compartments
(Fig. 1C), could be seen in H78-C10.0 cells. The observed
HLA-DR staining in these cells is not a consequence of
a nonspecific background, as A3.01 (a T CD4 HLA-DR-
human-derived cell line) treated in the same conditions
showed no staining at all (Fig. 1C). The fact that H78-
C10.0 cells express lower amounts of HLA-DR than H78-
D2.2 might be either the consequence of a poor HLA-DR
transcription or the mistargeting to degrading compart-
ments, or both.
HLA-DR molecules are upregulated at the surface of
H78-C10.0 cells upon infection by HIV-1
When H78-D2.2 cells were infected by HIV-1HX10, no
major changes were observed in HLA-DR cell surface
expression (compare Figs. 2C and 2D), whereas the
TABLE 1
Detection of Cell-Surface Antigens on H78-C10.0
and H78-D2.2 Cells
Antigen Antibody
Cell surface antigen
detection
Cell line
H78-C10.0 H78-D2.2
CD2 CD2X11  
CD3 T3 / 
CD4 13.B.8.12  
CD6 BL-TP6a  
CD7 Leu9  
CD11a CBR-LFA-1/10 / 
CD18 CRBM1/19  
CD25 P55 / 
CD27 1A4  
CD43 10G7  
CD44 50B4  
CD45 GAP8.3  
CD46 122.2  
CD47 BRIC126  
CDw50 CRB-IC3/6  
CD59 YTH53.1 / 
HLA-DR L243  
CD63 H5C6  
Note. HUT78 derived cell lines were both tested for the presence of
a variety of T cell surface antigens at their plasma membrane by FACS
analysis as described under Materials and Methods. () mean fluo-
rescence intensity (mfi) lower than 6; (/) 6  mfi  10, () 11 
mfi  50; () 55  mfi  100; () mfi  101.
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majority of the H78-C10.0-infected cells became positive
(Fig. 2B). This unexpected result could be due either to
the incorporation of HLA-DR molecules from the input
virus envelope into the target cell membrane, as has
already been reported (Saifuddin et al., 1998), or to a
specific HLA-DR cell-surface upregulation. In a way to
distinguish between these two possibilities, we analyzed
the class II surface content of the infectious virus prog-
eny. A3.01, H78-D2.2, and H78-C10.0 cells were infected,
at a multiplicity of infection (m.o.i.) of 0.5, with HIV-1HX10
grown in HUT78 cells. Equal amounts of infectious virus
(see Materials and Methods) from culture supernatant of
infected cells at Day 7 postinfection were serially diluted
and incubated in wells precoated with an anti-HLA-DR
antibody. After many washes, H9 cells were added to
each well, and the infectivity of the captured virus was
tested on the basis of p24 production in the supernatant
at Day 7. Table 2 shows, as expected, that infectious
FIG. 1. HLA-DR heterodimers are differentially localized in H78-C10.0
and H78-D2.2 cells. (A) FACS analysis of HUT78-derived cell lines.
H78-C10.0 and H78-D2.2 cells were double stained for 1 h at 4°C in
FACS buffer, with biotinylated Q4120 monoclonal antibody (for CD4) and
PE-conjugated L243 monoclonal antibody (for HLA-DR). Cell-associ-
ated Q4120 monoclonal antibodies were labeled for 1 h with FITC-
conjugated streptavidin. (B) HLA-DR complex immunoprecipitated from
HUT78-derived cell lines. The equivalent of 5 105, H78-D2.2 cells, and
107 H78-C10.0 cells immunoprecipitated with L243 mouse mAb (Lanes
1 and 3) or control mouse IgG (Lanes 2 and 4) were loaded on a 15%
PAGE and treated as described under Materials and Methods. (C)
Intracellular localization of HLA-DR and LAMP-2 molecules by immu-
nofluorescence staining. Detergent-treated H78-D2.2 (1), A3.01 (2), and
H78-C10.0 (3 and 4) cells were stained with L243 mouse mAb (1
through 3) or H4B4 mouse mAb (4), for LAMP-2, as described under
Materials and Methods.
FIG. 2. HLA-DR membrane upregulation in H78-C10.0 cells upon
HIV-1 infection. FACS analysis of double-stained 4 days infected cells
with PE-conjugated L243 mouse mAb and HIVIg antibodies. Cell-sur-
face associated HIVIg antibodies were labeled for 1 h at 4°C with
FITC-conjugated goat anti-human IgG. (A and B) H78-C10.0 cells, (C
and D) H78-D2.2. Infected cells are represented in B and D, and
noninfected cells in A and C, respectively.
TABLE 2
Detection of Viral Particles Harboring HLA-DR at Their Surface
in Supernatants of Infected Cells
HIV-1 producer
cell line
p24 detected in H9 cell-culture supernatants
Dilution of HIV-1 producer cell-line supernatant
retained on anti-HLA-DR mAb
1:25 1:75 1:225 1:675 1:2025
A3.01     
H78-C10.0     
H78-D2.2     
Note. In a 96-well plate, 4 105 H9 cells were incubated with several
dilutions of L243 monoclonal antibody captured viruses produced by
the studied cell lines as well as A3.01, an HLA-DR CD4 human T cell
line, as described under Materials and Methods. Productive infection
was determined at day 7 by the presence of soluble p24 antigen,
measured by ELISA. () p24 concentration  0.5 ng/ml; () p24
concentration  0.5 ng/ml.
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virus produced by A3.01 cells was not retained by anti-
HLA-DR antibodies, suggesting that input virus does not
have an effect on levels of class II molecules incorpo-
rated into de novo produced virus. In contrast, infectious
viral particles produced by H78-D2.2 cells and H78-C10.0
cells were retained by anti-HLA-DR antibodies. These
results indicate that HLA-DR on H78-C10.0 cells is of
cellular origin and not from the virus input.
HIV-1 Gag induces HLA-DR plasma membrane
expression in H78-C10.0 cells
To determine which of the viral proteins is involved in
promoting the surface expression of HLA-DR in H78-
C10.0, H78-D2.2 and H78-C10.0 cells were subjected to
transient expression of gag-pro or env HIV-1 genes using
recombinant vaccinia vectors. Twenty hours postinfec-
tion, an aliquot of the treated cells was surface stained
for HLA-DR detection, while the remaining cells were
35S-labeled to immunoprecipitate the radiolabeled neo-
synthesized viral proteins. Indeed, Fig. 3B shows that in
vaccinia-infected cells the HIV-related proteins were
translated, since Pr55gag (gag) and gp160/120 (env)
were immunoprecipitated with a pool of IgGs from sero-
converted individuals. FACS analysis of H78-C10.0-
treated cells, represented in Fig. 3A, upper panel, shows
HLA-DR molecules at the plasma membrane only in cells
expressing the gag gene and not in cells expressing the
env gene. The input of the protease expression is not
relevant since the expression of Pr55gag alone is suffi-
cient to bring HLA-DR molecules at the plasma mem-
brane (data not shown). No cell membrane associated
class II molecules could be observed in those cells
infected with the env-expressing vector, or the wild-type
vaccinia vector. No significant changes in plasma mem-
brane associated HLA-DR were observed in H78-D2.2
cells expressing any of the tested viral proteins (Fig. 3A,
lower panel).
Gag expression in H78-C10.0 cells does not increase
HLA-DR transcript level
The HIV Gag-related protein p17 MA is known to be a
component of a nucleoprotein complex named the pre-
integration complex (PIC) involved in the transport of de
novo synthesized viral DNA from the cytoplasm to the
nucleus of the infected cell. Although no information is
available concerning the involvement of p17 in any reg-
ulatory event in cellular gene transcription (Freed, 1998),
we decided to rule out the possibility that Gag-depen-
dent HLA-DR phenotype shift observed in H78-C10.0
cells might be at a transcriptional level. To determine
whether a significant change in HLA-DR -chain mRNA
occurred upon gag expression, serial dilutions of an
aliquot of total RNA extracted from Gag expressing, or
nonexpressing H78-C10.0 and H78-D2.2 cells, were sub-
jected to RT-PCR as described under Materials and
Methods. The last RNA dilution in H78-C10.0, as in H78-
D2.2 cells, where the expected 320-bp amplified frag-
ment could be observed by ethidium bromide staining on
the separating agarose gel, corresponds to 12 ng (Fig. 4,
upper panel). Although our assay is only semiquantita-
tive, no significant increase in the level of HLA-DR 
transcript after expression of the viral gag gene in both
FIG. 3. HIV-1 Gag protein is involved in HLA-DR surface expression in H78-C10.0 cells. (A) FACS analysis of HUT78-derived cell lines expressing
only one viral protein. Recombinant or wild-type vaccinia vector (v11kGAG2, v11kENV5, or wt)-infected cells were recovered 18 h postinfection and
stained for HLA-DR cell-surface expression with PE-conjugated L243 mAb. Results are expressed as the percentage of cells carrying the HLA-DR
epitope at their surface. H78-C10.0, top; H78-D2.2, bottom. (B) Immunoprecipitation of 35S-metabolically labeled viral proteins expressed by the
recombinant vaccinia: v11kENV5, top; v11kGAG2, bottom; infected cells as described under Material and Methods. Lane 1 represents 5  105
H78-D2.2-treated cells, and Lane 2 represents 5  106 H78-C10.0-treated cells.
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cell types was observed. Moreover, Gag expression in
both cells resulted in a small but equivalent drop of about
three folds, of the amount of specific HLA-DR - (Fig. 4,
upper panel) and -actin (Fig. 4, lower panel) mRNAs,
due to vaccinia infection (data not shown). The molecular
basis of this behavior, which was observed in three
independent experiments, is still unclear.
The viral glycoprotein precursor gp160 is differentially
posttranslationally processed in H78-C10.0 cells
Since the gag component of HIV-1 appears to be
responsible for the restoration of class II plasma mem-
brane localization in infected H78-C10.0 cells, we might
expect that for at least a small number of other cellular
proteins expressed in H78-C10.0, the same event(s)
should be modified. As shown in Table 1, only membrane
expression of HLA-DR was found to be impaired among
the several cellular antigens tested. We thus looked into
surface expression of the viral glycoprotein precursor,
gp160, the only viral protein that transits through the
secretory pathway on its way to the plasma membrane.
During this vesicular transport, it encounters furin, or a
furin-like cellular protease, resident of a post-Golgi com-
partment, involved in the specific cleavage leading to the
formation of the viral gp120/gp41 heterodimer. Targeting
to the plasma membrane of env-related proteins is inde-
pendent from this posttranslation processing (Moulard et
al., 1999), but only the oligomerized heterodimer is able
to induce fusion (Bolmstedt et al., 1991) with cell mem-
branes expressing CD4 and a member of the chemo-
kine-receptor family, such as CXCR4 or CCR5. The re-
sulting fusion product can be monitored as large multinu-
cleated cells, called syncytia. We took advantage of the
fact that gp120 colocalizes with HLA-DR in intracellular
vesicular structures, as was strongly suggested for HIV-
1-infected macrophages (G. Raposo, personal communi-
cation), and we investigated whether or not gp120 ex-
pression differs in H78-C10.0 and H78-D2.2 cells. To
determine the posttranslational pattern of gp160, HUT78-
derived cell lines were infected with a recombinant vac-
cinia vector containing the env viral gene sequence.
Surface staining of env-related proteins was performed
on the cells 12 h postinfection, using an antibody recog-
nizing gp160 as well as gp120. The results, presented in
Fig. 5, show that similar levels of the viral gene products
were present at the plasma membrane of H78-C10.0 and
H78-D2.2 cell lines infected with env-encoding vaccinia.
We then monitored the syncytia formation phenotype in
both types of infected cells. Env-expressing H78-D2.2
cells formed extensive syncytia, whereas Env expressing
H78-C10.0 cells did not (Table 3). However, after coex-
pression of gag and env, syncytia formation was ob-
served to the same extent both in H78-C10.0 and in
H78-D2.2 cells (Table 3). This suggests that Gag expres-
sion could restore functional Env at the surface of H78-
C10.0 cells.
We further analyzed the posttranslational modifica-
tions of gp160 in H78-C10.0 cells. Proteins from cells
transiently expressing the viral env gene were radiola-
beled, and the Env-related molecules were immunopre-
cipitated, to determine the mature to nonmature viral
glycoprotein ratio. Figure 6 represents the percentage of
immunoprecipitated gp160 or gp120 from the total viral
glycoprotein. The results clearly show that H78-C10.0
cells poorly mature the glycoprotein precursor (Fig. 6A),
whereas the presence of Pr55gag (Fig. 6B) resulted in
FIG. 5. Expression of HIV-1 env gene in H78-C10.0 and H78-D2.2
cells results in the presence of the viral glycoprotein gp160 and/or
gp120 at the cell surface. FACS analysis of vaccinia virus (vector) or
v11kENV5 (env) infected H78-C10.0 and H78-D2.2 cells. Cells were
incubated for 1 h in FACS buffer with HIVIg antibodies and stained with
FITC-conjugated goat anti-human antibodies.
FIG. 4. HLA-DR transcript level is not upregulated by HIV-1 Gag
protein expression. Trizol-purified, cell-related RNA from Gag express-
ing (v11kGAG2) and nonexpressing (no) cells was submitted to RT-PCR
using the primer pairs, allowing the amplification of a 320-bp fragment
specific to HLA-DR  mRNA (top), or a 366-bp fragment specific to
-actin (bottom). The amount of total RNA used in each single enzy-
matic reaction was as follows: a, 333 ng; b, 111 ng; c, 37 ng; d, 12.3 ng;
e, 4.1 ng; f, 1.4 ng. In (a) 333 ng total RNA was submitted only to PCR
amplification. (*) shows the specific amplified DNA fragment.
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the restoration of gp160 cleavage (Fig. 6A) as compared
to the histogram profile found for the viral glycoprotein
expressed in H78-D2.2 cells.
The compiled data presented here demonstrate that
impaired HLA-DR, and gp160 intracellular transport in
H78-C10.0 cells, can be rescued by the expression of the
HIV-1 Gag precursor.
DISCUSSION
In this study we show that HIV-1 Gag can restore
defective transport of HLA-DR to the surface of H78-
C10.0 cells. In the absence of HIV-1 Gag, HLA-DR mol-
ecules are localized in intracellular compartments of
H78-C10.0 cells. This is likely to be due to a transport
defect situated in a particular pathway leading from a
sorting intracellular organelle, such as a post-Golgi ves-
icle, to the cell membrane. Previous data invoked that
viral glycoproteins encounter MHC class II molecules in
post-Golgian intracellular compartments (G. Raposo,
personal communication), indicating that they might
share the same specific transport pathway from this
organelle to the plasma membrane. Interestingly, the
viral glycoprotein precursor that is normally proteolyti-
cally processed by furin or a furin-like cellular protease
in a post-Golgi compartment to its final mature products
was mostly found in its uncleaved form at the surface of
env-expressing H78-C10.0 cells. A possible explanation
might be that the gp160 molecule that reaches the
plasma membrane did not encounter the cellular pro-
tease. In this way, mature and nonmature env-related
proteins would be engaged in different intracellular path-
ways just before reaching the furin-like rich compart-
ment, as was suggested elsewhere (Moulard et al.,
1999). Our results reexamine this hypothesis. Indeed, env
expression in H78-C10.0 cells did not induce syncytia,
whereas the presence of large multinucleated cells was
scored in H78-D2.2 env-expressing cells. Moreover, the
immature-over-mature glycoprotein ratio (gp160/gp120)
TABLE 3
Syncitia Scoring of Gag, Env, or Gag-Env Expressing Cells
Cell line
Syncitia formation by cells infected with
No Vector v11kENV5 v11kGAG2 v11kG2E5
H78-D2.2     
H78-C10.0   /  
Note. Recombinant vaccinia infected cells were scored 18 h postin-
fection for multinucleated cell formation by light microscope. ()
more than 85% of the cells formed large syncitia in five different fields.
(/) only a few (less than seven) small syncitia were observed in five
different fields.
FIG. 6. HIV-1 Gag protein expression is necessary for correct gp160 maturation in H78-C10.0 cells. Equal amounts of Env or Env- and
Gag-expressing cells were radiolabeled, as described under Materials and Methods. Detergent-soluble cell lysates were incubated with HIVIg
antibodies and Protein A Sepharose beads in lysis buffer. The immunoprecipitated material was submitted to a 7% SDS–PAGE; the gel was dried and
an autoradiography was obtained (A). Results are expressed for each sample as the percentage of mature (gp120 in gray) and immature (gp160 in
black) viral glycoprotein out of total expressed viral glycoprotein, after quantification of the intensity of the mature and immature glycoprotein using
the NIH Image software. (B) To verify the biosynthesis of Gag, immunoblot was performed on nonradioactive recombinant vaccinia (v11kG2E5)-
infected cell lysates with HIVIg antibodies.
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in env-expressing H78-C10.0 cells was found to be
higher than in H78-D2.2 expressing the same viral gene.
The most striking and interesting result we have ob-
tained was the finding that the expression of the viral gag
gene in H78-C10.0 cells is sufficient to restore both
defective HLA-DR and gp160 posttranslational events.
While Gag-expressing H78-D2.2 cells did not show any
significant changes in gp160 processing or HLA-DR cell-
surface expression, H78-C10.0 cells expressing this spe-
cific structural viral gene became HLA-DR cell-surface
positive. The coexpression with the env gene resulted, in
this cell type, in a gain of function of the syncytia phe-
notype through a more efficient cleavage of gp160 to its
functional gp120/gp41 mature products.
The same results were obtained when the Gag pre-
cursor was expressed in its viral environment. HIV-1
infection of H78-C10.0 cells induced HLA-DR surface
expression. De novo plasma membrane anchored
HLA-DR molecules behave, in terms of their ability to
become an integral envelope protein of the emerging
virions, in a similar way as described for virus budding
from HLA-DR/CD4 T cells (Arthur et al., 1992; Ott, 1997;
Saarlos et al., 1997). Furthermore, the newly produced
virions harbored functional gp120/gp41 heterodimers as
they were found to be infectious (Table 2). This might
imply that the virus has developed a mechanism
whereby Pr55gag protein must interact with the intracel-
lular transport machinery to assure the presence of
some cellular and viral proteins at the plasma mem-
brane, such as HLA-DR and functional gp120/gp41. We
would thus expect that a clear Gag-dependent rescuing
phenotype would be observed only in cells presenting a
certain transport defect similar to in H78-C10.0. How
could HIV-1 Gag rescue HLA-DR transport in these cells?
HLA-DR is thought to interact with the viral matrix protein
in the viral particle as does the cytoplasmic tail of gp41
(Freed and Martin, 1996). We can thus hypothesize that
interactions between the cytoplasmic tail(s) of HLA-DR
heterodimers and the matrix region of the Gag precursor,
on its way to the plasma membrane, would play a key
role in this event. Although we do not know the molecular
mechanism governing the observed Gag-dependent res-
toration of HLA-DR plasma membrane transport, it is not
surprising that to increase its infectious ability, via
HLA-DR recruitment, HIV would create a sophisticated
strategy involving molecular interactions with cellular
elements. Indeed, a direct correlation between viral in-
fectivity and the presence of HLA-DR at the surface of the
producing cells has been reported (P. Guschankof and
M. Suzan, unpublished observation; Cantin et al., 1997).
A remarkable example of HIV-1:HLA-DR functional inter-
action was published last year by Saifuddin and col-
leagues (2000). They found that HIV-1 expression can be
enhanced by CIITA, the HLA-DR transactivator element,
through activation of the viral LTR promoter, indepen-
dently of Tat or other viral accessory proteins. Our pre-
sented data and their results suggest that HLA-DR is an
important cellular partner for HIV-1 infectious particle
production. It can also be proposed, in a more general
retroviral perspective, that Pr55gag due to its biochemi-
cal properties, and in particular its ability to autooli-
gomerize and to bind to a lipid bilayer, could be func-
tionally related to partners of cellular-coating proteins
known to be involved in transport vesicle budding (Webre
et al., 1998; reviewed in Allan and Balch, 1999). Interest-
ingly, Amigorena and co-workers (Thery et al., 1999)
showed that the Gag precursor of murine leukemia virus
are associated with the exosomal membrane in nonin-
fected murin dendritic cells. In two recent articles (Gar-
rus et al., 2001; VerPlank et al., 2001) it was clearly shown
that the human Tsg101 protein known to be involved in
MVB protein sorting (Bishop and Woodman, 2001) inter-
acts physically with the p6 domain of the Gag precursor
and that this interaction is crucial for the late viral bud-
ding event. This is the first evidence for a tight functional
relationship between the cellular trafficking apparatus
and the HIV-1 budding. It is important to point out that in
both events we have observed, i.e., transport of HLA-DR
heterodimers to the plasma membrane and gp160 pro-
teolytic maturation, transport through late endosomal
compartments, i.e., MVB, is involved, implying that, as for
Tsg101, the machinery governing endosomal sorting is
tightly implicated in Pr55Gag budding. Understanding
the molecular mechanism of HLA-DR transport rescue by
Gag polyprotein would provide new information on viral–
host relationships.
MATERIALS AND METHODS
Cell culture
HUT-78-derived cell lines were maintained at 37°C in
a 7.5% CO2 atmosphere in RPMI medium supplemented
with 10% FCS, glutamine, penicillin, and streptomycin.
Virus infections
HIV-1HX10 molecular clone (Fisher et al., 1988) grown in
HUT78 cells was used as viral source. Infections were
performed in supplemented RPMI medium at 37°C, at a
cell density of 5 to 10  106 cells/ml for 3 h on gentle
shaking. Cells were then diluted 40-fold in culture me-
dium and kept at 37°C. Medium was changed every 2 to
3 days and kept frozen for p24 quantification which was
performed by an ELISA assay as described elsewhere
(Moore et al., 1990) using the AMPAK amplification kit
(DAKO, Trappes, France).
Vaccinia recombinant expression vectors were a kind
gift from Dr. Shiu-Lok Hu (Bristol-Myers Squibb Pharma-
ceutical Research Institute, WA) (Haffar et al., 1990). The
Gag-expressing construction, v11kGAG2, contains the
first 4000 nt of the gag-pol gene of HIV-ILAI, where a
nonsense codon has been inserted at position 1537,
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allowing the expression of the Gag and Pro proteins. The
v11kENV5 expresses the Env glycoprotein of HIV-ILAI, and
the recombinant virus v11kG2E5 expresses proteins
from all of the genomic regions described above. Vac-
cinia infections were performed at 1 PFU per cell, 3 h at
37°C on gentle shaking in nonsupplemented RPMI me-
dium at a cell density of 5 to 10 106 cells/ml. Cells were
then diluted 40-fold in supplemented RPMI medium and
kept at 37°C.
Solid-phase antibody capture of HLA-DR virus and
measurement of captured virus infectivity
This assay was described elsewhere (Gluschankof et
al., 1997). Briefly, a 96-well ELISA plate was coated with
L243 monoclonal antibody directed to HLA-DR het-
erodimers and nonspecific sites were blocked. Viral su-
pernatants pelleted for 10 min at 70,000 g through a 20%
sucrose cushion were normalized to as 5  106 infec-
tious particles/ml. Twenty-five microliters of serial three-
fold dilution of this material was added to the wells. After
4 h incubation at RT, the unbound material was removed,
and the plate was washed. To determine the relative
amount of virus captured, 4  105 H9 cells were added
to each well and the presence of soluble p24 antigen
was determined by ELISA at Day 7 postinfection.
FACS analysis
An amount of 2  105 cells was stained with a primary
antibody at 5 g/ml in 200 l FACS buffer (PBS, 0.1% FCS,
0.02% sodium azide) at 4°C for 1 h. After several washes
with FACS buffer, cells were fixed overnight at 4°C in
0.05% formaldehyde in PBS. Chromophore-conjugated
secondary antibodies diluted to a final concentration of
10 g/ml in FACS buffer were added, when necessary, to
the washed fixed cells, for 1 h at 4°C. The stained cells
were analyzed by Cell Quest software in a Becton–
Dickinson FACScan machine (Becton–Dickinson, San Di-
ego, CA).
HLA-DR heterodimers were stained with PE-conju-
gated mouse monoclonal L243 antibody (Becton–Dickin-
son). CD4 molecules were stained with biotinylated
mouse monoclonal Q4120 antibodies (Sigma, St. Louis,
MO) and FITC-conjugated streptavidin (Sigma).
Viral glycoproteins were stained with a purified IgG
fraction of seroconverted patients (HIVIg), obtained from
the NIH AIDS Research & Reference Reagent Program
(Rockville, MD), followed by incubation with FITC-conju-
gated goat anti-human IgG antibodies (Immunotech,
Marseilles, France).
For all other cell-surface antigens tested we used as a
first antibody, mouse monoclonal antibodies obtained
from the Fifth International Leukocyte Typing Workshop
Antibody Panel. PE-conjugated goat anti-mouse Fc anti-
bodies(Immunotech) were used as a second layer. Non-
relevant mouse isotype antibody was used as negative
control and subtracted from the experimental values.
Immunofluorescence cellular staining
An amount of 2  105 cells adsorbed on poly-L-lysine-
pretreated glass slide was washed several times with
PBS, before fixation with 4% PAF (paraformaldehyde) in
PBS for 30 min at RT. After several washes with PBS,
inactivation of the remaining PAF was achieved by 30
min incubation with 0.1 M glycine/PBS followed by PBS
washes. Cells were then permeabilized for 30 min with
PBS/0.05% saponin/0.2% BSA and incubated for 1 h at RT
with purified L243 mouse monoclonal antibody (20 g/ml
final concentration), or H4B4 purified mouse anti-human
CD107b (LAMP-2) monoclonal antibody, purchased from
Pharmingen (San Diego, CA) (20 g/ml final concentra-
tion) in the same buffer. Fluorescent staining of treated
cells was done by 1 h incubation, at RT, with FITC-
conjugated goat anti-mouse Fc fragment, 5 g/ml final
concentration (Immunotech).
35S-labeling, immunoprecipitation, and immunoblotting
An amount of 107 infected or noninfected cells was
radiolabeled for 6 h at 37°C in 10 ml RPMI medium
lacking cysteine and methionine, with 3 mCi of a mixture
of [35S]Met and [35S]Cys (NEN, U.K.). Cells were washed
several times and lysed for 15 min on ice with 1 ml lysis
buffer (0.15 M NaCl, 20 mM Tris-HCl pH 7.4, 1% Triton
X-100, 1% SDS, containing a cocktail of protease inhibi-
tors from Boehringer Mannheim, Meylan, France). After
clarification of the lysate, by 15 min centrifugation at
14,000 rpm in an Eppendorf microfuge, the soluble ma-
terial was precleared overnight at 4°C with 15 l of a 1:1
vol:vol suspension of Protein A Sepharose beads (Phar-
macia, Uppsala, Sweden) in lysis buffer. The supernatant
was then incubated with either HIVIg, or L243 mouse
monoclonal antibody, or mouse IgG (5 g) and 15 l
Protein A Sepharose (suspension 1:1) for 3 h at 4°C on a
rotator. After several washes with lysis buffer, the im-
mune complexes, adsorbed on the beads, were solubi-
lized with 50 l Laemmli buffer (containing 2% SDS and
2% -mercaptoethanol) and separated on a SDS–7%
PAGE. The acrylamide gel was dried and processed for
autoradiography. The relative amount of immunoprecipi-
tated gp120 and/or gp160 was scored on screened au-
toradiographs using the NIH Image software.
For Western blot analysis 105 gag-env recombinant
vaccinia infected cells were lysed 18 h postinfection with
100 l Laemmli buffer. The solubilized material was
submitted to a SDS–10% PAGE. Blotting of the separated
proteins on a nitrocellulose membrane, Hybond ECL
(Amersham Pharmacia Biotech, U.K.) was performed on
a Transblot, semidry apparatus (Bio-Rad, France). Blotted
proteins were incubated first, with HIVIg at a final con-
centration of 20 g/ml in PBS, 1% nonfat dry milk, 0.2%
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Tween 20, 1 h at room temperature. After several washes
in the same buffer, a second incubation with horseradish
peroxidase conjugated pig anti-human antibodies
(DAKO, Trappes, France) was performed. The membrane
was incubated with ECL (Amersham Pharmacia Biotech),
and Gag-related molecules were visualized by autora-
diography.
RT-PCR
Total RNA was extracted from infected and nonin-
fected cells using Trizol (BRL) following the protocol
proposed by the manufacturer. The obtained material
was treated with 1 unit RNase-free DNase. Different
amounts of RNA were subjected to RT-PCR amplification
to allow semiquantitative detection of specific mRNAs
coding for -actin or HLA-DR -chain.
HLA-DR  chain forward primer, 5CCCCAGTGCTT-
GAGAAGAGGCTCATCC3, is situated in the second exon
of the gene, and the antisense primer, 5CCACGTTCTCT-
GTAGTCTCTGGG3, is situated in the third exon of the
gene. The expected amplified spliced fragment is of 320
bp.
-actin sense primer, 5ATCTGGCACCACACCTTCTA-
CAATGAG3, is situated in the second exon of the gene,
and the -actin antisense primer, 5CGTGGTGGTG-
AAGCTGTAGCCGCGCTC3, is situated in the third exon
of the gene. The expected amplified spliced fragment is
of 366 bp.
RT-PCR amplifications were performed with the Super-
script kit (BRL). Retrotranscription was done by 30 min
incubation at 45°C followed by 3 min at 94°C. DNA was
amplified by 30 cycles of 1 min incubation at 94°C,
followed by 1 min at 56°C and 1 min at 72°C. Final
elongation was done at 72°C for 5 min. PCR amplifica-
tion was performed with Taq polymerase (BRL). The
products were separated on a 2% agarose gel electro-
phoresis and visualized under long-wave UV light expo-
sure.
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